New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Cyendiv (Nintedanib Capsules)

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email to discuss.

  • Brand Name- Cyendiv
  • Innovator Brand Name- Ofev & Vargatef
  • API- Nintedanib
  • Packaging- 60 Capsules
  • Strength- 100 mg, 150 mg
  • Manufacturer Name- Boehringer Ingelheim

South Delhi Pharma can facilitate the supply of “Cyendiv (Nintedanib)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Cyendiv (Nintedanib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Category Tag
Category Tag

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

Query Form


What Cyendiv is?

Nintedanib is a pharmaceutical drug that inhibits tyrosine kinase and indicated for the treatment of:

  • Idiopathic Pulmonary Fibrosis: Nintedanib used to treat the IPF (Idiopathic Pulmonary Fibrosis). It works in order to block such substances that cause IPF.
  • Non-Small Cell Lung Cancer (NSCLC): In combination with docetaxel for the patient with locally advanced, metastatic or locally recurring non-small cell lung cancer. Nintedanib can be used as a second-line treatment with a combination of Docetaxel.

What Nintedanib is?

Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

In March 2020, it was approved for use in the United States to treat chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). It is the first treatment for this group of fibrosing lung diseases that worsen over time that was approved by the U.S. Food and Drug Administration (FDA).

Related Products